KR880002531A - 폴리엔 항진균성 항생제를 캡술화한 인지질 입자의 사용하는 개선된 전신 진균 간염 치료 방법 - Google Patents
폴리엔 항진균성 항생제를 캡술화한 인지질 입자의 사용하는 개선된 전신 진균 간염 치료 방법 Download PDFInfo
- Publication number
- KR880002531A KR880002531A KR870009101A KR870009101A KR880002531A KR 880002531 A KR880002531 A KR 880002531A KR 870009101 A KR870009101 A KR 870009101A KR 870009101 A KR870009101 A KR 870009101A KR 880002531 A KR880002531 A KR 880002531A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- phospholipid
- polyene antifungal
- cholesterol
- antifungal antibiotic
- Prior art date
Links
- 230000000843 anti-fungal effect Effects 0.000 title claims 9
- 229940121375 antifungal agent Drugs 0.000 title claims 9
- 150000004291 polyenes Chemical class 0.000 title claims 8
- 150000003904 phospholipids Chemical class 0.000 title claims 7
- 239000002245 particle Substances 0.000 title claims 5
- 230000009885 systemic effect Effects 0.000 title claims 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 230000002538 fungal effect Effects 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 11
- 230000003115 biocidal effect Effects 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 6
- 239000008346 aqueous phase Substances 0.000 claims 5
- JCZPMGDSEAFWDY-MBMOQRBOSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-MBMOQRBOSA-N 0.000 claims 3
- 150000002016 disaccharides Chemical class 0.000 claims 3
- 150000002772 monosaccharides Chemical class 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- VQJHQYFOCBRCGA-QTVWNMPRSA-N (2s,3s,4s,5s)-6-amino-2,3,4,5,6-pentahydroxyhexanal Chemical group NC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O VQJHQYFOCBRCGA-QTVWNMPRSA-N 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000002337 glycosamines Chemical class 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 1
- 229960003942 amphotericin b Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960000988 nystatin Drugs 0.000 claims 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (24)
- 적어도 하나의 인지질 및 콜레스테롤로 되고, 저이온 강도 수용액 상중에 현탁시킨 2000미만의 인지질 입자 중에 캡슐화된 폴리엔 항진균성 항생제로 되는 주입가능한 조성물.
- 제 1 항에 있어서, 폴릴엔 항진균성 항생제가 암포테리신 B 및 니스타틴으로 되는 군 중에서 선택되는 조성물.
- 제 1 항에 있어서, 상기 입자가 작고, 단층판의 소포인 조성물.
- 제 1 항에 있어서, 상기 입자가 입자 표면에 중량된 아민을 갖는 조성물.
- 제 4 항에 있어서, 중량된 아민이 아미노당인 조성물.
- 제 5 항에 있어서, 아미노당이 콜레스테롤의 6-아미노만노오스 유도체인 조성물.
- 제 6 항에 있어서, 조성물이 약0% 내지 약20%가 6-아미노만노오스 유도체인 조성물.
- 제 1 항에 있어서, 폴리엔 항진균성 항생제, 적어도 하나의 인지질, 콜레스테롤 및 아미노만노오스가 5-15물%의 폴리엔 항진균성 항생제, 40-90몰%의 인지질, 0.10-40몰%의 콜레스테롤 및 0-20몰%의 아미노만노오스의 몰%비로 존재하는 조성물.
- 제 1 항에 있어서, 폴리엔 항진균성 항생제의 몰%가 약 5% 내지 약 15%인 조성물.
- 제 8 항에 있어서, 폴리엔 항진균성 항생제, 적어도 하나의 인지질, 콜레스테롤 및 아미노만노오스의 몰비가 0.2:2:1인 조성물.
- 제 1 항에 있어서, 인지질이 포스파티딜글리세롤, 포스파디닐콜린, 포스파티닐세린, 포스파티딜에탄올아민 및 포스파티드 산으로 되는 군 중에서 선택되는 조성물.
- 제 11 항에 있어서, 포스파티딜콜린이 계란 포스파티딜콜린, 콩 포스파티딜콜린, 디미리스토일포스파티틸콜린, 디팔미토일포스파티딜콜린 및 디스테아로일포스파티딜콜린의 조성물.
- 제 1 항에 있어서, 콜레스테롤이 약 0.1% 내지 약 40%의 몰%로 존재하는 조성물.
- 제 1 항에 있어서, 저이온강도의 수용액상이 20밀리몰 미만의 조성물.
- 제 1 항에 있어서, 수용액 상의 pH가 약 pH 6.0 내지 약8.0인 조성물.
- 제 1 항에 있어서, 수용액상이 당용액인 조성물.
- 제16항에 있어서, 당용액이 트리스 완충액으로 완충된 단당류로 되는 조성물.
- 제17항에 있어서, 단당류가 글루코오스, 과당 및 갈락 토오스로 되는 군 중에서 선택되는 조성물.
- 제 1 항에 있어서, 수용액상이 약 4.0 내지 약6.0 중량%의 단당류로 되는 조성물.
- 제16항에 있어서, 당 용액이 트리스 완충액으로 완충된 이당류로 되는 조성물.
- 제20항에 있어서, 이당류가 수쿠로오스 및 락토오스로 되는 군 중에서 선택되는 조성물.
- 제 1 항에 있어서, 수용액상이 약 8.0 내지 약 10.0중량%이 이당류로 되는 조성물.
- 제 1 항에 있어서, 폴리엔 항진균성 항생제의 농도가 적어도 0.5mg/ml 폴리엔 항진균성 항생제인 조성물.
- 제 1 항, 제 4 항, 제 8 항, 제 11 항, 제 15 항 또는 제16항의 조성물을 정맥내 투여하는 것으로 되는 전신 진균 감염 치료 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89906486A | 1986-08-21 | 1986-08-21 | |
| US899.064 | 1986-08-21 | ||
| US06/899,064 | 1986-08-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR880002531A true KR880002531A (ko) | 1988-05-09 |
| KR950013747B1 KR950013747B1 (ko) | 1995-11-15 |
Family
ID=25410437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019870009101A KR950013747B1 (ko) | 1986-08-21 | 1987-08-20 | 폴리엔 항진균성 항생제를 캡술화한 인지질 입자의 제조 방법 및 이 인지질 입자로 이루어진 제약 조성물 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5874104A (ko) |
| EP (1) | EP0260811B1 (ko) |
| JP (1) | JPH0615475B2 (ko) |
| KR (1) | KR950013747B1 (ko) |
| AT (1) | ATE66597T1 (ko) |
| AU (1) | AU606880B2 (ko) |
| CA (1) | CA1292184C (ko) |
| DE (1) | DE3772498D1 (ko) |
| DK (1) | DK168982B1 (ko) |
| ES (1) | ES2051740T3 (ko) |
| GR (1) | GR3002852T3 (ko) |
| HK (1) | HK115393A (ko) |
| IE (1) | IE60901B1 (ko) |
| NO (1) | NO174833C (ko) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2620028B2 (fr) * | 1986-12-05 | 1994-02-25 | Ire Celltarg Sa | Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant |
| CA1338736C (fr) * | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation |
| US4812312A (en) * | 1987-03-03 | 1989-03-14 | Board Of Regents Of The University Of Texas System | Liposome-incorporated nystatin |
| US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
| CA1338702C (en) * | 1987-03-05 | 1996-11-12 | Lawrence D. Mayer | High drug:lipid formulations of liposomal- antineoplastic agents |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US4999199A (en) * | 1988-11-10 | 1991-03-12 | Board Of Regents, The University Of Texas System | Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics |
| EP0598116B1 (en) * | 1989-11-27 | 1996-07-24 | Nippon Shinyaku Company, Limited | Fat emulsion |
| CA2099772A1 (en) * | 1991-01-14 | 1992-07-15 | Gabriel Lopez-Berestein | Anti-hiv activity of liposomal nystatin and amphotericin b |
| EP0664130A1 (en) * | 1991-10-25 | 1995-07-26 | Senju Pharmaceutical Co., Ltd. | External preparation for treating hemorrhoidal diseases |
| JP2915296B2 (ja) * | 1993-08-30 | 1999-07-05 | 宇野 潤 | 抗真菌製剤 |
| GB9519654D0 (en) * | 1995-09-27 | 1995-11-29 | Nycomed Imaging As | Stabilised phospholipid compositions |
| JP2000505789A (ja) * | 1996-01-25 | 2000-05-16 | シェリング アクチェンゲゼルシャフト | 注射及び輸液用として血管内に使用する改良された濃縮溶液 |
| GB9721901D0 (en) * | 1997-10-16 | 1997-12-17 | Univ Manchester | Particles |
| AU1350099A (en) * | 1997-12-01 | 1999-06-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Formulations for topical treatment of skin infections |
| IT1301807B1 (it) * | 1998-06-25 | 2000-07-07 | Tiberio Bruzzese | Formulazioni farmaceutiche iniettabili di derivati della partricina. |
| US6613352B2 (en) | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
| US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
| JP4786041B2 (ja) * | 2001-03-02 | 2011-10-05 | 丸善製薬株式会社 | 渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤 |
| US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
| US20070212703A1 (en) * | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
| RU2457854C2 (ru) * | 2005-12-30 | 2012-08-10 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед | Длительное высвобождение нейрегулина для улучшения сердечной функции |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| US8039450B2 (en) | 2008-03-06 | 2011-10-18 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
| DK2393828T3 (en) | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| DK2440241T3 (en) | 2009-06-08 | 2017-10-02 | Amunix Operating Inc | GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF |
| ES2705249T3 (es) | 2009-06-08 | 2019-03-22 | Amunix Operating Inc | Polipéptidos reguladores de glucosa y métodos para su producción y uso |
| US20120172429A1 (en) | 2009-07-10 | 2012-07-05 | Woolf Clifford J | Permanently charged sodium and calcium channel blockers as anti- inflammatory agents |
| US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
| RU2481100C2 (ru) * | 2009-10-16 | 2013-05-10 | Лайфкеа Инновейшнз Пвт. Лтд. | Новая лекарственная форма для лечения грибковой инфекции |
| CA2778678A1 (en) | 2009-10-30 | 2011-05-05 | Cns Therapeutics, Inc. | Improved neurturin molecules |
| AU2010330747B2 (en) | 2009-12-18 | 2016-08-11 | Achelios Therapeutics, Inc. | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions |
| WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
| JP5936002B2 (ja) * | 2010-11-19 | 2016-06-15 | 北海道公立大学法人 札幌医科大学 | 組合わせ医薬製剤 |
| US10370430B2 (en) | 2012-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
| SG11201404885RA (en) | 2012-02-15 | 2014-09-26 | Amunix Operating Inc | Factor viii compositions and methods of making and using same |
| TR201808753T4 (tr) | 2012-06-08 | 2018-07-23 | Alkermes Pharma Ireland Ltd | Agonistler ve antagonistler olarak dairesel permütasyon tarafından modifiye edilmiş ligandlar. |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| JP6608422B2 (ja) | 2014-03-25 | 2019-11-20 | ザ ガバメント オブ ザ ユナイテッド ステイツ，アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー | モノホスホリルリピッドａ（ｍｐｌａ）含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤 |
| EP3226972A4 (en) | 2014-12-01 | 2018-08-08 | Achelios Therapeutics, Inc. | Methods and compositions for treating migraine and conditions associated with pain |
| RU2018107695A (ru) | 2015-08-03 | 2019-09-05 | Президент Энд Феллоуз Оф Гарвард Колледж | Заряженные блокаторы ионных каналов и способы их применения |
| AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
| EP3370730A4 (en) | 2015-11-06 | 2019-07-31 | Adjuvance Technologies, Inc. | TRITERPENIC SAPONIN ANALOGS |
| JP2019532027A (ja) | 2016-08-17 | 2019-11-07 | ソルスティス バイオロジクス，リミティッド | ポリヌクレオチド構築物 |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| KR20200098476A (ko) | 2017-10-16 | 2020-08-20 | 아쥬반스 테크놀로지스 인코포레이티드 | 트리테르펜 사포닌 유사체 |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| KR20210145164A (ko) | 2019-03-11 | 2021-12-01 | 녹시온 테라퓨틱스 인코포레이티드 | 에스테르 치환된 이온 채널 차단제 및 사용 방법 |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| SG11202109720WA (en) | 2019-03-11 | 2021-10-28 | Nocion Therapeutics Inc | Charged ion channel blockers and methods for use |
| AU2020237474A1 (en) | 2019-03-11 | 2021-09-30 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2021091586A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10842798B1 (en) | 2019-11-06 | 2020-11-24 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| AU2021236130A1 (en) | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2023175454A1 (en) | 2022-03-14 | 2023-09-21 | Pfizer Inc. | Methods for producing an adjuvant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310505A (en) * | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
| US4497791A (en) * | 1983-02-10 | 1985-02-05 | Vestar Research Incorporated | Method for labeling phagocytic cells |
| GB2135647A (en) * | 1983-02-15 | 1984-09-05 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
| PT78628B (en) * | 1984-05-02 | 1986-06-18 | Liposome Co Inc | Pharmaceutical composition with reduced toxicity |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| IE58659B1 (en) * | 1984-10-22 | 1993-11-03 | Vestar Inc | Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors |
| US4753788A (en) * | 1985-01-31 | 1988-06-28 | Vestar Research Inc. | Method for preparing small vesicles using microemulsification |
| US4766046A (en) * | 1985-09-27 | 1988-08-23 | Liposome Technology, Inc. | Stabilized liposome/amphotericin composition and method |
| US4812312A (en) * | 1987-03-03 | 1989-03-14 | Board Of Regents Of The University Of Texas System | Liposome-incorporated nystatin |
-
1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-14 EP EP87307221A patent/EP0260811B1/en not_active Expired - Lifetime
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active IP Right Cessation
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
-
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
-
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/xx not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK434187D0 (da) | 1987-08-20 |
| AU606880B2 (en) | 1991-02-21 |
| NO873492L (no) | 1988-02-22 |
| NO174833B (no) | 1994-04-11 |
| EP0260811B1 (en) | 1991-08-28 |
| NO174833C (no) | 1994-07-20 |
| GR3002852T3 (en) | 1993-01-25 |
| IE872148L (en) | 1988-02-21 |
| KR950013747B1 (ko) | 1995-11-15 |
| EP0260811A2 (en) | 1988-03-23 |
| IE60901B1 (en) | 1994-08-24 |
| DE3772498D1 (de) | 1991-10-02 |
| JPS6366123A (ja) | 1988-03-24 |
| ATE66597T1 (de) | 1991-09-15 |
| JPH0615475B2 (ja) | 1994-03-02 |
| EP0260811A3 (en) | 1988-07-20 |
| HK115393A (en) | 1993-11-05 |
| AU7716087A (en) | 1988-02-25 |
| US5874104A (en) | 1999-02-23 |
| CA1292184C (en) | 1991-11-19 |
| ES2051740T3 (es) | 1994-07-01 |
| DK434187A (da) | 1988-02-22 |
| DK168982B1 (da) | 1994-07-25 |
| NO873492D0 (no) | 1987-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880002531A (ko) | 폴리엔 항진균성 항생제를 캡술화한 인지질 입자의 사용하는 개선된 전신 진균 간염 치료 방법 | |
| KR870700001A (ko) | 리포좀의 보존방법 | |
| US4235877A (en) | Liposome particle containing viral or bacterial antigenic subunit | |
| US4199565A (en) | Liposome particle containing viral or bacterial antigenic subunit | |
| US5376380A (en) | Method of producing liposomal products from freeze or spray-dried preparations of liposomes | |
| KR890701093A (ko) | 아라키돈산 대사물질 관련 리포좀 제조방법 및 그 제제 | |
| AU587600B2 (en) | Method for preserving liposomes | |
| Al-Shakhshir et al. | Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| KR19990028383A (ko) | 신규한 보조제 조성물 및 이것을 함유한 백신 제제 | |
| ES8505545A1 (es) | Un procedimiento para producir un preparado de gamma-interferon estable | |
| KR910011900A (ko) | 글리코펩티드 항생물질의 안정화 조성물 | |
| Cano-Mancera et al. | Inhibition of the adhesion of Entamoeba histolytica trophozoites to human erythrocytes by carbohydrates | |
| Yoshihara et al. | Invitro demonstration by the rate assay of the presence of small pore in the outer membrane of Pseudomonasaeruginosa | |
| Opekarová et al. | Nystatin changes the properties of transporters for arginine and sugars An in vitro study | |
| Vertut-Croquin et al. | Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability | |
| CA2179899A1 (en) | Synthetic Glycoamines that Promote or Inhibit Cell Adhesion | |
| JPH06211645A (ja) | リポソーム凍結乾燥製剤 | |
| Basu et al. | Release of a lectin from a fatty acid auxotroph of Saccharomyces cerevisiae grown in presence of oleic acid | |
| White et al. | Pore properties of the Golgi membrane from lactating-rat mammary gland. Effects of pH and temperature and reconstitution into phospholipid vesicles | |
| Thomson et al. | The kinetics of dihydrostreptomycin uptake in Pseudomonas putida membrane vesicles: absence of inhibition by cations | |
| Adamkiewicz | Blood sugar levels and allergies | |
| KR860000073A (ko) | 기계적 응력에 대해 안정화된 수성인슐린 제제의 제조방법 | |
| Masson-Pévet et al. | About the presence of nexuses between leading sinus node cells | |
| Deleers et al. | Facilitated fusion of liposomes with glycerol monoleate planar bilayer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20091117 Year of fee payment: 15 |
|
| EXPY | Expiration of term |